LSP SCN8
Alternative Names: LSP-SCN8Latest Information Update: 28 Oct 2023
At a glance
- Originator LifeSplice
- Class Antiepileptic drugs; Antisense oligonucleotides
- Mechanism of Action NAV1.6 voltage-gated sodium channel expression modulators; RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Dravet syndrome
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Dravet-syndrome in USA
- 05 Jul 2021 LSP SCN8 is available for licensing as of 05 Jul 2021. http://lifesplicepharma.com/investors-partners/
- 15 Sep 2019 LifeSplice receives NIH phase I/phase II SBIR Fast-Track CREATE grant from National Institutes of Health for LSP SCN8 development in Dravet Syndrome